Filing Flows

Filing Flows › 8-K events › Repligen

Repligen: entry into a material definitive agreement

Form 8-K filed Nov 6, 2026 · items 1.01, 2.03, 3.02

What the filing says

On November 6, 2026, in connection with the consummation of previously announced private exchange and subscription transactions, Repligen Corporation (the “Company”) issued $1.0 billion aggregate principal amount of its 0.25% Convertible Senior Notes due 2031 (the “New Notes”) under an Indenture, dated November 6, 2026

ScaleThe filing names $1.00B: about 119% of Repligen's annual revenue ($837.3M, four times the latest quarter), or 4.8 quarters of sales.

Read the filing on SEC EDGAR →

What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Item 2.03: 0.0% next session across 13,268. Item 3.02: +0.1% next session across 2,750. Every item ranked →

What this kind of filing means

Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.

Item 2.03 — Creation of a direct financial obligation. New debt or a guarantee: the amount, the rate and the maturity set the cost of capital and the repayment wall ahead.

Repligen at a glance

Latest quarterQ3 2026
Revenue$209.3M
Revenue Y/Y+11%
Operating margin-14.1%
IndustryBiological Products, (No Diagnostic Substances)

Repligen, Q3 2026: revenue $209M (+11% year over year), operating margin -14.1%. The chart follows the revenue to costs, profit and cash.

Repligen: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent debt and financing

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.